Live
- Hyderabad: Will end 4% quota for Muslims in TS says Amit Shah
- Jagan failed to keep poll promises: Sharmila
- Beware of Jagan’s dramas, cautions Naidu
- Hyderabad: Ghose panel to quiz KCR
- Viveka Murder: Avinash innocent, asserts Jagan
- Viveka’s wife questions Jagan’s move to field Avinash
- New Delhi: 88 seats in 13 states go for polling today
- YSRCP misrule will end soon in AP, says Piyush
- Hyderabad: People have no sympathy for KCR, says Revanth Reddy
- Why has BJP failed to end paper leaks in UP?
Biocon launches Hepatitis C drug
Highlights
Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C.
New Delhi : Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C.
CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to patients in India at a fraction of the global cost of the innovator brand, Biocon Ltd said in a statement.
The cost of a 12-week course of this combination therapy in the US is $94,500 (about Rs 63 lakh).
Biocon, President-Marketing, Ravi Limaye said the introduction of CIMIVIR-LTM will strengthen the company's current portfolio of virology products. "It furthers our commitment to offer affordable therapy for unmet patient needs in debilitating and life-threatening conditions," he added.
CIMIVIR-L is an equivalent of the innovator product commercialised by Gilead Sciences in the US. Biocon had entered into a licensing agreement last year with US-based Gilead to manufacture and commercialise its chronic Hepatitis-C blockbuster product range, Sofosbuvir and Sofosbuvir-Ledipasvir combination in India and in select emerging markets.
These territories account for more than 50 per cent of the global Hepatitis C prevalence.
The Drugs Controller General of India (DCGI) recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a license from Gilead.
Next Story
ADVERTISEMENT
